Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 60.65
+1.50 (2.54%)
Sep 5, 2025, 4:08 PM HKT
Everest Medicines Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
| 851.28 | 706.68 | 125.93 | 12.79 | 0.05 | - | Upgrade | |
Revenue Growth (YoY) | 103.39% | 461.16% | 884.46% | 23588.89% | - | - | Upgrade |
Cost of Revenue | 254.08 | 177.79 | 34.41 | 4.65 | 0.02 | - | Upgrade |
Gross Profit | 597.21 | 528.89 | 91.52 | 8.15 | 0.03 | - | Upgrade |
Selling, General & Admin | 896.3 | 758.15 | 396.57 | 603.23 | 440.83 | 311.08 | Upgrade |
Research & Development | 470.1 | 528.04 | 540.05 | 809.74 | 613.43 | 377.41 | Upgrade |
Other Operating Expenses | -43.02 | 22.92 | 6.16 | -0.12 | -4.96 | -0.98 | Upgrade |
Operating Expenses | 1,323 | 1,309 | 942.78 | 1,413 | 1,049 | 687.51 | Upgrade |
Operating Income | -726.17 | -780.21 | -851.27 | -1,405 | -1,049 | -687.51 | Upgrade |
Interest Expense | -22.9 | -22.19 | -23.06 | -5.59 | -4.81 | -33.87 | Upgrade |
Interest & Investment Income | 74.46 | 95.21 | 107.67 | 38.48 | 28.88 | 2.04 | Upgrade |
Currency Exchange Gain (Loss) | 14.95 | 19.51 | -28.07 | -155.18 | 22.94 | -0.85 | Upgrade |
Other Non Operating Income (Expenses) | -2.46 | 2.65 | 2.82 | -1.61 | -6.46 | -4,938 | Upgrade |
EBT Excluding Unusual Items | -662.12 | -685.03 | -791.91 | -1,529 | -1,009 | -5,658 | Upgrade |
Gain (Loss) on Sale of Investments | -0.01 | -0.01 | 0.85 | -21.75 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.03 | - | -1.43 | 1,320 | - | - | Upgrade |
Asset Writedown | - | -356.34 | -51.97 | -16.49 | - | - | Upgrade |
Other Unusual Items | 3.41 | - | - | - | - | - | Upgrade |
Pretax Income | -658.75 | -1,041 | -844.46 | -247.28 | -1,009 | -5,658 | Upgrade |
Income Tax Expense | - | - | - | 0.01 | - | - | Upgrade |
Net Income | -658.75 | -1,041 | -844.46 | -247.28 | -1,009 | -5,658 | Upgrade |
Net Income to Common | -658.75 | -1,041 | -844.46 | -247.28 | -1,009 | -5,658 | Upgrade |
Shares Outstanding (Basic) | 323 | 321 | 313 | 298 | 293 | 85 | Upgrade |
Shares Outstanding (Diluted) | 323 | 321 | 313 | 298 | 293 | 85 | Upgrade |
Shares Change (YoY) | 0.25% | 2.51% | 5.18% | 1.49% | 243.61% | 1532.82% | Upgrade |
EPS (Basic) | -2.04 | -3.24 | -2.70 | -0.83 | -3.44 | -66.29 | Upgrade |
EPS (Diluted) | -2.04 | -3.24 | -2.70 | -0.83 | -3.44 | -66.29 | Upgrade |
Free Cash Flow | -487.68 | -744.92 | -886.53 | -1,512 | -839.89 | -480.5 | Upgrade |
Free Cash Flow Per Share | -1.51 | -2.32 | -2.83 | -5.08 | -2.86 | -5.63 | Upgrade |
Gross Margin | 70.15% | 74.84% | 72.67% | 63.69% | 57.41% | - | Upgrade |
Operating Margin | -85.30% | -110.41% | -675.97% | -10981.12% | -1943096.30% | - | Upgrade |
Profit Margin | -77.38% | -147.36% | -670.57% | -1933.11% | -1867998.15% | - | Upgrade |
Free Cash Flow Margin | -57.29% | -105.41% | -703.97% | -11817.36% | -1555344.44% | - | Upgrade |
EBITDA | -594.67 | -670.04 | -795.72 | -1,391 | -1,043 | -683.03 | Upgrade |
EBITDA Margin | -69.86% | -94.82% | - | - | - | - | Upgrade |
D&A For EBITDA | 131.5 | 110.17 | 55.55 | 13.81 | 6.21 | 4.48 | Upgrade |
EBIT | -726.17 | -780.21 | -851.27 | -1,405 | -1,049 | -687.51 | Upgrade |
EBIT Margin | -85.30% | -110.41% | - | - | - | - | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.